Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

Sleep Solutions (Glen Burnies, MD) a commercial-stage medical device and diagnostics company focused on obstructive sleep apnea, closed a $20M Series F financing. Participants include Quaker BioVentures, Johnson & Johnson Dev Corp., TPG Growth, MedVenture Associates, Emergent Ventures and Lava Ventures.

NiTi Surgical Solutions (Israel) a commercial-stage medical device company focused on tissue-closure of colorectal and and gastric disease requiring anastomoses, closed a $18.5M Series F financing. Participants include Forbion Capital Partners, Evergreen Venture Partners, Israel Healthcare Ventures, Meakem Becker Venture Capital and Alice Ventures, and SCP Vitalife.

CardioMEMS (Atlanta, GA) a commercial-stage medical device company with an approved endovascular abdominal aortic aneurysm pressure management system and clinical-stage wireless sensing device for management of cardiovascular diseases such as aneurysms, heart failure and hypertension, closed a $22.1M Series F financing. Participants may have included Arcapita Ventures, Boston Millennia Partners, Medtronic, Easton Capital Partners, Foundation […]

Helicon Therapeutics (San Diego, CA) a clinical-stage biotech focused on the development of modulating memory formation from short-term memories, and the conversion of short-term memory to long-term memory, closed a $50M Series F financing. Participants in the round were not named

Synageva BioPharma (Waltham, MA) a clinical-stage biopharma and developer of the Synageva Expression Platform, an integrated platform of vectors and protein production, processing and purification systems used to develop their pipeline of monoclonal antibodies, cytokines, and biosimilars, closed a $33M Series X financing. Participants inlcude Baker Brothers Investments, Tullis Health Investors, Four Partners, Yasuda Enterprise […]

iScience Interventional (Menlo Park, CA) a commercial-stage microcatheter device for the treatment of ocular diseases open-angle glaucoma and clinical-stage development focused on wet-AMD, closed a $20.5M Series F financing. Participants include Affinity Capital Management, Johnson & Johnson Development Corp., L Capital Partners, Clarian Health Ventures, Prism VentureWorks, Three Arch Ventures, DeNovo Ventures and Asset Management […]

BioVex (Woburn, MA) a clinical-stage therapeutic vaccine company focused on metastatic melanoma, closed a $40M Series F financing. Participants include Forbion Capital Partners, Credit Agricole Private Equity, Harris & Harris Group, Innoven Partners, New Science Ventures, Triathlon Medical Venture Partners and Scottish Equity Partners.

Sangart (San Diego, CA) a clinical-stage artificial blood substitute focused on targeting oxygen delivery to tissues that are insufficiently oxygenated, closed a $50M Series F financing, the final tranche of the $100M round. Participants include Leucadia National who owns approximately 92% of the company after investing approximately $146.2M since 2003.

Precision Therapeutics (Pittsburgh, PA) developer of diagnostics to determine likely response to a various cancer drugs or combinations, closed a $43M Series F financing. Participants include Longitude Venture, Adams Capital Management, Quaker BioVentures, Birchmere Ventures, Techno Venture Management and Draper Triangle Ventures.

Vapotherm (Stevensville, MD), a developer of high flow oxygen therapy products, closed a $20.5M Series F financing. Participants include GE Asset Management, Cross Creek Capital and Integral Capital Partners.

PatientKeeper (Newton, MA) commercial-stage provider of integrated physician information systems, closed a $7.5M Series F financing. Participants include Frazier Healthcare Ventures, Whitney & Co. and New Enterprise Associates.

Merrimack Pharmaceuticals (Cambridge, MA) development-stage biotechnology company focused on novel treatments for autoimmune disease and cancer, closed a $60M Series F financing. Participants include Credit Suisse First Boston, Next Fund, Crocker Ventures, HNI Holdings, Noonday Asset Management, TPG-Axon Capital, and WT Investment Advisors Fund.

Microbia (Cambridge, MA) rational drug designer focused on GI and cardiovascular therapeutics raised a $50M series F round. The financing was led by Ridgeback Capital and joined by Morgan Stanley Investment Management.

« Previous Page  Next Entries »

to top of page...